89 unusually experienced at operating through uncertainty, combining institutional durability with a concentration of innovation that US healthcare companies can deploy globally. For strategic buyers, growth investors and healthcare operators prepared to engage thoughtfully, this distinctive combination helps explain why Israel is likely to remain a leading source of transaction activity, partnership opportunities and long-term strategic value in the years ahead. Author info: Ron Abelski is Co-Head of Epstein Rosenblum Maoz’s (ERM) Corporate and M&A Department and leads its Healthcare & Life Sciences practice. He advises global healthcare companies, investors, and strategic acquirers on complex cross-border M&A and investment transactions in Israel. ISRAEL — HEALTHCARE
RkJQdWJsaXNoZXIy MjgzNzA=